Format

Send to

Choose Destination
Expert Opin Drug Saf. 2015 Jun;14(6):795-800. doi: 10.1517/14740338.2015.1034105. Epub 2015 Apr 7.

Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events.

Author information

1
Kansai Electric Power Hospital, Center for Diabetes, Endocrinology and Metabolism , 2-1-7 Fukushima-ku, Osaka 553-0003 , Japan +81 6 6458 5821 ; +81 6 6458 6994 ; ydaisuke-kyoto@umin.ac.jp ; seino.yutaka@e2.kepco.co.jp.

Abstract

Sodium/glucose co-transporter 2 inhibitors (SGLT2i) represent a novel class of glucose-lowering agents that lower plasma glucose levels through pharmacological inhibition of glucose reuptake from the kidney, independent of insulin secretion and action. Clinical trials of SGLT2i demonstrated therapeutic benefits on glycemic control and bodyweight in individuals with type 2 diabetes, with few cases of serious adverse events (SAEs). However, a considerable number of SAEs were reported in patients receiving SGLT2i clinically in Japan during the first 3 months of their use. These included urogenital infections, hypoglycemia and dehydration. Unexpectedly, serious skin and subcutaneous disorders, mainly reported as generalized rash or skin eruption, were prominent in patients receiving SGLT2i, but with unknown mechanisms. There is also concern for potential SAEs associated with chronic SGLT2i administration, especially in the non-obese type 2 diabetes characterized by reduced insulin secretion often seen in East Asia. Chronic SAEs may include severe hypoglycemia due to depletion of hepatic glycogen storage, acceleration of diabetes-associated sarcopenia and ketosis/ketoacidosis. The current information on acute SAEs confirms the importance of caution in the appropriate use of SGLT2i. Furthermore, careful long-term observation of patients receiving SGLT2i is essential to avoid SAEs and for better clinical use of this drug class.

KEYWORDS:

dehydration; hypoglycemia; serious adverse events; sodium/glucose co-transporter 2 inhibitors; urogenital infections

PMID:
25851664
DOI:
10.1517/14740338.2015.1034105
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center